Online clinical pathway for managing adults with chronic kidney disease

Arora P Vasa P Brenner D . Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ 2013;185:E417-23.

Jafar TH Schmid CH Landa M . Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.

Lewis EJ Hunsicker LG Clarke WR . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

Wright JT Jr Bakris G Greene T Agodoa LY. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002;288:2421-31.

Tonelli M Moye L Sacks FM . Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14:1605-13.

Mann JFE Gerstein HC Pogue J . Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.

Weiner DE Tighiouart H Amin MG. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307-15.

Shlipak M Heidenreich P. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002;137:555-62.

Tonelli M Bohm C Pandeya S Gill J. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001;37:484-9.

Stevens L Fares G Fleming J. Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol 2005;16:2439-48.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150.

Rotter T Kinsman L James E . Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. Cochrane Database Syst Rev 2010;(3):CD006632.

Allen D Gillen E Rixson L. Systematic review of the effectiveness of integrated care pathways: what works, for whom, in which circumstances? Int J Evid Based Healthc 2009;7:61-74.

Sulch D Perez I Melbourn A Kalra L. Randomized controlled trial of integrated (managed) care pathway for stroke rehabilitation. Stroke 2000;31:1929-34.

Cunningham S Logan C Lockerbie L . Effect of an integrated care pathway on acute asthma/wheeze in children attending hospital: cluster randomized trial. J Pediatr 2008;152:315-20.

Canadian Pharmacists Association. Pharmacists’ expanded scope of practice in Canada. 2014. Available: www.pharmacists.ca/index.cfm/pharmacy-in-canada/scope-of-practice-canada/ (accessed December 5, 2014).

Alberta College of Pharmacists. The health professional’s guide to pharmacist prescribing. 2012. Available: https://pharmacists.ab.ca/sites/default/files/HPGuidePrescribing.pdf (accessed December 5, 2014).

Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013;3:1-305.

Tobe S Stone J Brouwers M . Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative. CMAJ 2011;183:1135-50.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can J Diabetes 2013; 37(Suppl 1):S1-212.

Tanguay J-F Bell AD Ackman ML . Focused 2012 update of the Canadian Cardiovascular Society Guidelines for the use of antiplatelet therapy. Can J Cardiol 2013;29:1334-45.

Anderson TJ Grégoire J Hegele RA . 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67.

Hackam DG Quinn RR Ravani P . The 2013 Canadian Hypertension Education Program (CHEP) recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013;29:528-42.

AHS Laboratory Services. Use of the CKD-EPI equation for reporting estimated glomerular filtration rate. 2013. Available: www.albertahealthservices.ca/LabServices/wf-lab-bulletin-use-of-ckd-epi-equation-egfr-final.pdf (accessed December 5, 2014).

Yusuf S Teo KK Pogue J . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.

Matsushita K van der Velde M Astor BC . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.

Hemmelgarn BR Manns BJ Lloyd A . Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-9.

James MT Hemmelgarn BR Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010;375:1296-309.

Tonelli M Muntner P Lloyd A . Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med 2011;154:12-21.

Strippoli GFM Craig M Deeks JJ . Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828-39.

Levey AS de Jong PE Coresh J . The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int 2011;80:17-28.

Chronic kidney disease (CKD) management in general practice . 2nd ed. Melbourne (AU): Kidney Health Australia; 2012.

Said S Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol 2014;3:99-104.

Jardine MJ Ninomiya T Perkovic V . Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010;56:956-65.

Pannu N Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med 2008;36(4 Suppl):S216-23.

Naughton C. Drug-induced nephrotoxicity. Am Fam Physician 2008;78:743-50.

Farag A Garg AX Li L Jain AK. Dosing errors in prescribed antibiotics for older persons with CKD: a retrospective time series analysis. Am J Kidney Dis 2014;63:422-8.

Aronoff GR Aronoff JR . Drug prescribing in kidney disease: can’t we do better? Am J Kidney Dis 2014;63:382-3.

Munar M Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician 2007;75:1487-96.